References
- 1. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561-1566.
- 2. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006; 48(5): 326-41. doi: 10.1016/j.pcad.2006.02.001. PMID: 16627048.
- 3. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens. 2001; 14(2): 174-82. doi: 10.1016/s0895-7061(00)01257-7. PMID: 11243310.
- 4. Cowan BR, Young AA. Left ventricular hypertrophy and reninangiotensin system blockade. Curr Hypertens Rep. 2009; 11(3): 167-172. doi:10.1007/s11906-009-0030-9
- 5. Shah AM, Hung CL, Shin SH, et al. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J. 2011; 162: 685-691.
- 6. Kuenzli A, Bucher HC, Anand I, et al. Metaanalysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One 2010; 5: e9946.
- 7. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316: 1429-1435. https://doi.org/10.1056/NEJM198706043162301
- 8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325: 293-302. https://doi.org/10.1056/NEJM199108013250501
- 9. Heusch G, Libby P, Gersh B. Cardiovascular remodeling in coronary artery disease and heart failure. Lancet. 2014; 383: 1933-1943.
- 10. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007; 292: 82-97.
- 11. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005; 289: H1560-H1566.
- 12. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
- 13. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005; 289: H2281-H2290.
- 14. Margonato D, Mazzetti S, De Maria R, et al. Heart Failure With Mid-Range Or Recovered Ejection Fraction: Differential Determinants Of Transition. CFR. 2020; 6: e28.
- 15. Albakri A. Heart failure with mid-range ejection fraction A review of clinical status and meta-analysis of clinical management methods. Trends in Research. 2018; 1(4): 1-2.
- 16. Nikolov A, Tzekova M, Kostov K, Blazhev A. Association between serum matrix metalloproteinase-12/angiotensin II profile and left ventricular hypertrophy in patients with heart failure. Arch. Balkan Medical Union. 2020; 55(2): 233-242.
- 17. Lehtonen AO, Puukka P, Varis J, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens. 2016; 34: 959-966.
- 18. Marwick TH, Gillebert TC, Aurigemma G et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging. 2015; 16: 577-605.
- 19. Weber K. Extracellular Matrix Remodeling in Heart Failure. A Role for De Novo Angiotensin II Generation. Circulation. 1997; 96(11): 4065-4082.
- 20. Dong B, Yu QT, Dai HY, et al. Angiotensin-converting enzyme- 2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol. 2012; 59: 739-747.
- 21. Feng Y, Hans C, McIlwain E, et al. Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. PLoS One 2012; 7: e48910.
- 22. Pei Z, Meng R, Li G, et al. Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs. Toxicol Lett 2010; 199: 173-181.
- 23. Johnson JA, West J, Maynard KB, Hemnes AR. ACE2 improves right ventricular function in a pressure overload model. 2011; PLoS One 6: e20828.
- 24. Flores-Muñz M, Godinho BM, Almalik A, Nicklin SA. Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor. 2012; PLoS One 7: e45564.
- 25. Hao PP, Liu YP, Hou GH, et al. Usefulness of angiotensin-( 1-7) to predict myocardial salvage after percutaneous coronary intervention in patients with acute myocardial infarction. Int J Cardiol. 2013; 168(1): 614-6. doi: 10.1016/j.ijcard.2013.01.206.
- 26. Hao PP, Chen YG, Liu YP. Association of plasma angiotensin-( 1-7) level and left ventricular function in patients with type 2 diabetes mellitus. 2013; PLoS One 8(5): e62788. https://doi:10.1371/journal.pone.0062788
- 27. Hisatake S, Kiuchi S, Kabuki T, et al. Serum angiotensinconverting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization. Heart Vessels. 2017; 32: 303-308. https://doi.org/10.1007/s00380-016-0877-z
- 28. Hisatake S, Kiuchi S, Kabuki T. The serum angiotensinconverting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction. Biosci Rep. 2020; 40(6): BSR20192701. doi:10.1042/BSR20192701
- 29. Wang K, Basu R, Poglitsch M, et al. Elevated Angiotensin 1-7/ Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure. Circ Heart Fail. 2020; 13(7): e006939. doi: 10.1161/CIRCHEARTFAILURE.120.006939.
- 30. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin- converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin–angiotensin system. J Endocrinol. 2013; 216: R1-R17.
- 31. Jones ES, Vinh A, McCarthy CA, et al. AT 2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008; 120: 292-316.
- 32. Ribeiro-Oliveira A, Nogueira AI, Pereira RM, et al. The reninangiotensin system and diabetes: an update. Vasc Health Risk Manag. 2008; 4(4): 787e803.